Enrico Attardi

Enrico Attardi

Auto-generated profile, based on publicly available information

Enrico Attardi

Department of Biomedicine and Prevention University of Rome Tor Vergata Rome Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2023 in Leukemia
Verified
Journal Article
Closed access
PDF file
TOTiziana Ottone
Tiziana Ottone
GSG. Silvestrini
G. Silvestrini
RPRocco Piazza
Rocco Piazza
Serena TravagliniSerena Travaglini
Serena Travaglini
CGCarmelo Gurnari
Carmelo Gurnari
MVMaria Teresa Voso
Maria Teresa Voso

15 July 2024 in HemaSphere
Verified
Journal Article
Open access
EAEnrico Attardi
Enrico Attardi
LTLucia Tiberi
Lucia Tiberi
GMGiorgio Mattiuz
Giorgio Mattiuz
DFDaniela Formicola
Daniela Formicola
EDElia Dirupo
Elia Dirupo
Valeria SantiniValeria Santini
Valeria Santini
Relevance of germline (GL) predisposition in myelodysplastic syndromes (MDSs) was stressed in both 2022 WHO and International Consensus classifications, but its incidence is probably underestimated, especially in young adult patients. We selected a cohort of 31 consecutive de novo MDS patients with unusual young age (<60 years). We performed exome sequencing (ES) on DNA extracted from noninvasive sources (peripheral blood and saliva), filtering for a panel of 344 genes specifically tailored for detecting GL variants related to clonal and nonclonal cytopenia. We observed at least one high‐ or low‐confidence GL MDS variant in 7/31 (22.6%) and 9/31 (29.0%) of cases, respectively. Four of 31 patients (12.9%) confirmed having established MDS/AML predisposing disorders. We found heterozygous variants in genes involved in DNA repair/cancer predisposition ( ATM, ATR, FANCM, PARN, BRCA1, BRCA2, CHEK2, MSH2 ) in 9/31 (29.0%) cases and variants affecting ribosome biogenesis ( SBDS ), hematopoietic stem cell ( GATA2 ), and megakaryocyte ( ANKRD26 ) differentiation in single cases. Two cases had variants in RBBP6 , a gene previously described exclusively in familial myeloproliferative neoplasms. Lastly, four cases had variants in genes related to inherited anemias ( CUBN and PIEZO1 genes). Our results showed that “young” MDS patients aged 40–60 years carried reported and unreported GL variants with an unexpectedly high proportion, and these events co‐occurred with somatic mutations recurrent in myeloid neoplasms. We explored the “no man's land” of the young adult MDS cases adopting a practical and scalable diagnostic tool, capable to detect GL variants avoiding invasive methods.

13 February 2026 in Journal of Human Immunity
Verified
Journal Article
Open access
PDF file
MMMattia Moratti
Mattia Moratti
BRBeatrice Rivalta
Beatrice Rivalta
ACAntonello Cardoni
Antonello Cardoni
VSVeronica Santilli
Veronica Santilli
EAEnrico Attardi
Enrico Attardi
FCFrancesca Conti
Francesca Conti
Inborn errors of immunity (IEI) are genetic disorders that not only heighten infection risk but also disrupt immune regulation, frequently leading to lymphoid tissue overgrowth known as lymphoid proliferations (LPD). We retrospectively reviewed 38 patients with genetically or clinically confirmed IEI and persistent LPD, comparing those with nonneoplastic/reactive hyperplasia to those who developed overt lymphoid neoplasm (lymphoma). Overall, 26% developed lymphoma—predominantly classical Hodgkin lymphoma or diffuse large B cell lymphoma—often after earlier IEI onset. Immunophenotyping and principal component analysis revealed that patients with common variable immunodeficiency developing Hodgkin lymphoma shared a distinctive T cell profile, differing from immunocompetent lymphoma cases. Centralized histologic re-evaluation reclassified several presumed lymphoma as nonneoplastic/reactive hyperplasia and identified Castleman-like and germinal center transformation patterns in nonneoplastic/reactive LPD. Notably, elevated blood IgM and circulating T follicular helper cells mirrored IgM deposits and PD-1+ T cells in lymph nodes. These findings highlight the importance of an integrated approach involving clinical, genetic, and pathological reviews to improve IEI diagnosis and avoid overtreatment.

3 December 2025 in Leukemia
Verified
Journal Article
Closed access
PDF file
CGCarmelo Gurnari
Carmelo Gurnari
HMHideki Makishima
Hideki Makishima
ADArda Durmaz
Arda Durmaz
EAEnrico Attardi
Enrico Attardi
RSRyunosuke Saiki
Ryunosuke Saiki
SOSeishi Ogawa
Seishi Ogawa

7 August 2024 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
MRMarco G. Raddi
Marco G. Raddi
SBSara Bencini
Sara Bencini
BPBenedetta Peruzzi
Benedetta Peruzzi
GMGiorgio Mattiuz
Giorgio Mattiuz
SPSven De Pourcq
Sven De Pourcq
Valeria SantiniValeria Santini
Valeria Santini
Flow cytometric analysis of erythroid precursors

13 May 2026 in Blood Advances
Verified
Journal Article
Open access
EAEnrico Attardi
Enrico Attardi
MCMarta Cipriani
Marta Cipriani
Luca GuarneraLuca Guarnera
Luca Guarnera
ASArianna Savi
Arianna Savi
Emiliano FabianiEmiliano Fabiani
Emiliano Fabiani
MVMaria Teresa Voso
Maria Teresa Voso
Secondary acute myeloid leukemia (AML) comprises heterogeneous entities, unified by poor prognosis. We evaluated the associations of genetic profiles with blast counts and patients’ history in a cohort of 924 patients with myelodysplastic syndrome (MDS)/AML or AML, classified according to the International Consensus Classification (ICC). The cohort included 109 patients with “mutated TP53,” 497 with “myelodysplasia-related (MDR) gene mutation,” 93 with “MDR-cytogenetic abnormality,” 77 were therapy-related, and 136 controls, categorized as “not otherwise specified” (NOS) AML. Exploring the ICC hierarchy, AML and MDS/AML categories with “mutated TP53” and “MDR-cytogenetic abnormality” presented similar biology and prognosis, irrespective of blast counts. Conversely, in MDS/AML with “MDR gene mutation” and NOS, profiles significantly differed from AML and were characterized by a higher number of mutations in STAG2, SRSF2, ASXL1 and TET2. This corresponded to improved survival in MDS/AML vs AML (MDR-gene mutation: median overall survival 24.8 vs 13.6 months, P< .0001; and NOS: 49.9 vs 19.2 months, P = .028). Within each ICC-defined AML category, a prior MDS history vs de novo onset did not impact on patients’ prognosis. We then analyzed secondary AML, defined by “prior MDS or MDS/MPN” or “therapy-related” (t-AML), as diagnostic qualifiers. According to European LeukemiaNet (ELN) 2022, AML progressing from MDS or MDS/myeloproliferative neoplasm (MPN) (AML post-MDS) mostly clustered in the adverse-risk group (84.1%), whereas t-AML showed more heterogeneous ELN profiles (12.9% favorable, 33.8% intermediate, and 53.3% adverse risk) reflecting diverse overall survival. Our findings underscore that genetic features and the ICC classification reliably capture disease biology, refine risk stratification, and ultimately guide treatment decisions in most secondary AML and MDS/AML.